Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 1/2012

01-01-2012 | Glaucoma

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

Authors: Akira Sawada, Tetsuya Yamamoto, Naoyoshi Takatsuka

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2012

Login to get access

Abstract

Introduction

To compare the intraocular pressure (IOP)-lowering effects of 0.005% latanoprost to that of 0.004% travoprost in eyes with open-angle glaucoma (OAG).

Methods

Forty-two patients with OAG who received either latanoprost or travoprost every evening for 12 weeks, and then switched to the other medication for another 12 weeks. The IOP measurements were made with a Goldmann applanation tonometer (GAT) at the baseline, and at 1, 3, 4, and 6 months after the treatment. The IOP at the untreated baseline and at the end of each treatment period was measured at 10:00, 12:00, and 16:00 hours. The central corneal thickness (CCT) was measured at each visit using an ultrasonic pachymeter.

Results

The mean baseline IOP was 13.9 ± 2.5 mmHg, and the CCT was 536.7 ± 30.5 μm. Latanoprost reduced the IOP by 2.5 ± 1.7 mmHg and travoprost by 2.6 ± 1.5 mmHg from the baseline (p = 0.6807). The CCT decreased significantly to 531.9 ± 30.3 at 3 months (p = 0.0160) and to 529.4 ± 30.5 μm at 6 months (p = 0.0002) after the therapy. The decrease was significantly greater in eyes after travoprost (p = 0.0049).

Conclusions

Travoprost has similar effect as latanoprost in reducing the IOP in glaucoma patients with relatively low IOPs. The use of prostaglandin analogs can decrease the CCT, and this change should be considered when the IOPs obtained by GAT are analyzed.
Literature
1.
go back to reference Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group, Japan Glaucoma Society (2004) The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology 111:1641–1648PubMed Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group, Japan Glaucoma Society (2004) The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology 111:1641–1648PubMed
2.
go back to reference Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497CrossRef Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497CrossRef
3.
go back to reference Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI (2008) Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17:217–222PubMedCrossRef Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI (2008) Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17:217–222PubMedCrossRef
4.
go back to reference Chew PT, RojanaPongpun P, Euswas A, Lu D, Chua J, Hui S, Rait J, Goldberg I, Li B, Travatan CACG Study Group (2006) Intraocular pressure-lowering effect and safety of travoprost 0.04% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol 8:13–19 Chew PT, RojanaPongpun P, Euswas A, Lu D, Chua J, Hui S, Rait J, Goldberg I, Li B, Travatan CACG Study Group (2006) Intraocular pressure-lowering effect and safety of travoprost 0.04% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol 8:13–19
5.
go back to reference Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472–484PubMedCrossRef Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472–484PubMedCrossRef
6.
go back to reference Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179–183PubMedCrossRef Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179–183PubMedCrossRef
7.
go back to reference Bean GW, Camras CB (2008) Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 53(suppl 1):S69–S84PubMedCrossRef Bean GW, Camras CB (2008) Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 53(suppl 1):S69–S84PubMedCrossRef
8.
go back to reference Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R (2007) A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther 29:1915–1923PubMedCrossRef Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R (2007) A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther 29:1915–1923PubMedCrossRef
9.
go back to reference Hepsen IF, Ozkaya E (2007) 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 21:453–458PubMed Hepsen IF, Ozkaya E (2007) 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 21:453–458PubMed
10.
go back to reference García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J (2006) Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22:1689–1697PubMedCrossRef García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J (2006) Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22:1689–1697PubMedCrossRef
11.
go back to reference Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J (2004) Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost. Clin Ther 26:84–91PubMedCrossRef Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J (2004) Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost. Clin Ther 26:84–91PubMedCrossRef
12.
go back to reference Yan DB, Battista RA, Haidich AB, Konstas AG (2008) Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr Med Res Opin 24:3023–3027PubMedCrossRef Yan DB, Battista RA, Haidich AB, Konstas AG (2008) Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr Med Res Opin 24:3023–3027PubMedCrossRef
13.
go back to reference Yildirim N, Sahin A, Gultekin S (2008) The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 17:36–39PubMedCrossRef Yildirim N, Sahin A, Gultekin S (2008) The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 17:36–39PubMedCrossRef
14.
go back to reference Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY (2004) Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness – a cross-sectional study on 403 eyes. Klin Monatsbl Augenheilkd 221:753–756PubMed Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY (2004) Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness – a cross-sectional study on 403 eyes. Klin Monatsbl Augenheilkd 221:753–756PubMed
15.
go back to reference Lass JH, Eriksson GL, Osterling L, Simpson CV, Latanoprost Corneal Effect Study Group (2001) Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 108:264–271PubMedCrossRef Lass JH, Eriksson GL, Osterling L, Simpson CV, Latanoprost Corneal Effect Study Group (2001) Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 108:264–271PubMedCrossRef
16.
go back to reference Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA (2008) Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 115:1550–1556PubMedCrossRef Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA (2008) Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 115:1550–1556PubMedCrossRef
17.
go back to reference Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD (2007) Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26:34–41PubMedCrossRef Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD (2007) Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26:34–41PubMedCrossRef
18.
go back to reference Stefan C, Dumitrica DM, Tebeanu E, Nae I, Sapundgieva A, Dragomir L (2007) Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95–99PubMed Stefan C, Dumitrica DM, Tebeanu E, Nae I, Sapundgieva A, Dragomir L (2007) Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95–99PubMed
19.
go back to reference Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, Koklu G (2008) Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398–402PubMedCrossRef Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, Koklu G (2008) Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398–402PubMedCrossRef
20.
go back to reference Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna R Jr (2009) The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25:51–53PubMedCrossRef Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna R Jr (2009) The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25:51–53PubMedCrossRef
21.
go back to reference Johnson TV, Toris CB, Fan S, Camras CB (2008) Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications. J Glaucoma 17:89–99PubMedCrossRef Johnson TV, Toris CB, Fan S, Camras CB (2008) Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications. J Glaucoma 17:89–99PubMedCrossRef
22.
go back to reference Johnson M, Kass MA, Moses RA, Crodzki WJ (1978) Increased corneal thickness simulating elevated intraocular pressure. Arch Ophthalmol 96:664–665PubMedCrossRef Johnson M, Kass MA, Moses RA, Crodzki WJ (1978) Increased corneal thickness simulating elevated intraocular pressure. Arch Ophthalmol 96:664–665PubMedCrossRef
23.
go back to reference Whitacre MM, Stein R (1993) Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 38:1–30PubMedCrossRef Whitacre MM, Stein R (1993) Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 38:1–30PubMedCrossRef
24.
go back to reference Whitracre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596 Whitracre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596
25.
go back to reference Brandt JD (2004) Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol 15:85–88PubMedCrossRef Brandt JD (2004) Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol 15:85–88PubMedCrossRef
26.
go back to reference Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 44:367–408PubMedCrossRef Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 44:367–408PubMedCrossRef
27.
go back to reference Suh MH, Park KH, Kim DM (2009) Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol 53:18–23PubMedCrossRef Suh MH, Park KH, Kim DM (2009) Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol 53:18–23PubMedCrossRef
28.
go back to reference Nomura Y, Nakamura S, Moriwaki M, Takahashi Y, Shiraki K (2010) Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol 4:643–647PubMed Nomura Y, Nakamura S, Moriwaki M, Takahashi Y, Shiraki K (2010) Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol 4:643–647PubMed
29.
go back to reference Ang GS, Kersey JP, Shepstone L, Broadway DC (2008) The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol 92:1129–1133PubMedCrossRef Ang GS, Kersey JP, Shepstone L, Broadway DC (2008) The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol 92:1129–1133PubMedCrossRef
30.
go back to reference Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 53:34–43CrossRef Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 53:34–43CrossRef
31.
go back to reference Whitacre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596PubMed Whitacre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592–596PubMed
32.
go back to reference Brandt JD, Beiser JA, Kass MA, Gordon MO (2001) Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:1779–1788PubMedCrossRef Brandt JD, Beiser JA, Kass MA, Gordon MO (2001) Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:1779–1788PubMedCrossRef
33.
go back to reference Iester M, Mete M, Figus M, Frezzotti P (2009) Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg 35:1623–1628PubMedCrossRef Iester M, Mete M, Figus M, Frezzotti P (2009) Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg 35:1623–1628PubMedCrossRef
34.
go back to reference Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH (2006) Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 141:1131–1133PubMedCrossRef Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH (2006) Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 141:1131–1133PubMedCrossRef
35.
go back to reference Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501–515PubMedCrossRef Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501–515PubMedCrossRef
36.
go back to reference Miglior S, Albe E, Guareschi M, Mandelli G, Gomarasca S, Orzalesi N (2004) Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness. Br J Ophthalmol 88:174–177PubMedCrossRef Miglior S, Albe E, Guareschi M, Mandelli G, Gomarasca S, Orzalesi N (2004) Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness. Br J Ophthalmol 88:174–177PubMedCrossRef
37.
go back to reference Wickham L, Edmunds B, Murdoch IE (2005) Central corneal thickness: will one measurement suffice? Ophthalmology 112:225–228PubMedCrossRef Wickham L, Edmunds B, Murdoch IE (2005) Central corneal thickness: will one measurement suffice? Ophthalmology 112:225–228PubMedCrossRef
38.
go back to reference Ornek K, Gullu R, Ogurel T, Ergin A (2008) Short-term effect of topical brinzolamide on human central corneal thickness. Eur J Ophthalmol 18:338–340PubMed Ornek K, Gullu R, Ogurel T, Ergin A (2008) Short-term effect of topical brinzolamide on human central corneal thickness. Eur J Ophthalmol 18:338–340PubMed
39.
go back to reference Smith VA, Hoh HB, Littleton M, Easty DL (1995) Over-expression of a gelatinase A activity in keratoconus. Eye 9:429–433PubMedCrossRef Smith VA, Hoh HB, Littleton M, Easty DL (1995) Over-expression of a gelatinase A activity in keratoconus. Eye 9:429–433PubMedCrossRef
40.
go back to reference Weinreb RN, Lindsey JD (2002) Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43:716–722PubMed Weinreb RN, Lindsey JD (2002) Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43:716–722PubMed
41.
go back to reference Mietz H, Schlötzer-Schrehardt U, Strassfeld C, Krieglstein GK (2001) Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 42:679–687PubMed Mietz H, Schlötzer-Schrehardt U, Strassfeld C, Krieglstein GK (2001) Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 42:679–687PubMed
42.
go back to reference Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (1999) Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117:794–801PubMed Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (1999) Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117:794–801PubMed
43.
go back to reference Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA, Group TS (2002) Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 109:998–1008PubMedCrossRef Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA, Group TS (2002) Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 109:998–1008PubMedCrossRef
44.
go back to reference Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147PubMed Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147PubMed
45.
go back to reference Peplinski LS, Albiani Smith K (2004) Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81:574–577PubMedCrossRef Peplinski LS, Albiani Smith K (2004) Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81:574–577PubMedCrossRef
46.
go back to reference Yang HK, Park KH, Kim TW, Kim DM (2009) Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 53:176–179PubMedCrossRef Yang HK, Park KH, Kim TW, Kim DM (2009) Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 53:176–179PubMedCrossRef
47.
go back to reference Yam JC, Yuen NS, Chan CW (2009) Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 25:471–472PubMedCrossRef Yam JC, Yuen NS, Chan CW (2009) Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 25:471–472PubMedCrossRef
Metadata
Title
Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma
Authors
Akira Sawada
Tetsuya Yamamoto
Naoyoshi Takatsuka
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2012
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-011-1762-1

Other articles of this Issue 1/2012

Graefe's Archive for Clinical and Experimental Ophthalmology 1/2012 Go to the issue